Therapeutics News and Research

RSS

Acorda's fourth quarter GAAP net income increases to $12.7 million

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2011.

16 Feb 2012

Drug companies forge joint ventures for smart pills

Imagine a "smart pill" containing a biodegradable electronic chip that monitors how your body responds to the medicine, broadcasts the information to your iPhone, which then emails the information to your physician.

16 Feb 2012

UC Cancer Institute to enroll up to 60 patients for AMG 595 phase-1 trial

The UC Cancer Institute is one of three centers internationally approved to test an experimental drug's safety and pharmacokinetics and also assess the clinical benefit against recurrent malignant glioma, an aggressive form of brain cancer.

16 Feb 2012

RUMC conducts early phase trial of MSDC-0160 for dementia

Researchers at Rush University Medical Center are conducting an early phase clinical trial of a novel drug therapy for patients with dementia due to Alzheimer's disease. The drug is a new compound called MSDC-0160, which is an insulin sensitizer that modulates mitochondrial metabolism.

16 Feb 2012

WSU's novel gene-therapy for blindness receives $250,000 FFB grant

Technology to restore vision through the use of a component of green algae - developed by a Wayne State University professor and scientific director of the Ligon Research Center of Vision at the Kresge Eye Institute - has attracted additional funding for therapy development.

16 Feb 2012

World Economic Forum releases list of 'Important Technologies'

The World Economic Forum's Global Agenda Council on Emerging Technologies has just released its list of "Important Technologies" that will change the world in the years ahead. The list highlights technology trends most likely to impact on the state of the world in the near future and was developed by a cross section of experts from science, businesses, and public policy.

15 Feb 2012

Ensysce announces latest data on delivery platform for therapeutic siRNA

Ensysce Biosciences Inc. announced today the publication of their latest data on their delivery platform for short interfering RNA (siRNA) for therapeutic purposes in the journal Materials.

14 Feb 2012

Alnylam commences underwritten public offering of 7,000,000 shares of common stock

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it has commenced an underwritten public offering of 7,000,000 shares of its common stock. All of these shares are being sold by Alnylam.

14 Feb 2012

Cardium to raise $5.0 million in registered direct offering

Cardium Therapeutics today announced that it has entered into definitive agreements with three institutional and accredited investors to sell an aggregate of 17,857,143 shares of its common stock in a registered direct offering for gross proceeds of approximately $5.0 million, before deducting placement agent's fees and estimated offering expenses.

13 Feb 2012

Discovery of novel rearrangements and fusions supports role for NGS in treatment of cancer

Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer gene analysis to routine clinical care, and Dana-Farber Cancer Institute today announced the Nature Medicine publication of results from their collaborative next-generation sequencing (NGS) study to assay cancer-relevant genes in 24 non-small cell lung cancer (NSCLC) and 40 colorectal cancer (CRC) cases.

13 Feb 2012

Study demonstrates dynamic genetic changes in ovarian cancers between diagnosis and recurrence

There is a need to analyze tumor specimens at the time of ovarian cancer recurrence, according to a new study published in Molecular Cancer Therapeutics.

13 Feb 2012

Linden to acquire SeraCare

SeraCare Life Sciences, Inc., a global life sciences company providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics, today announced that it has entered into a definitive agreement to be acquired by an affiliate of Linden Capital Partners, a Chicago-based private equity firm that focuses on middle market leveraged buyout investments in the healthcare and life science industries.

13 Feb 2012

Osiris provides update on status of development, commercialization agreement with Genzyme

Osiris Therapeutics, Inc., today provided an update on the status of the development and commercialization agreement with Genzyme, a Sanofi company.

10 Feb 2012

Automated insulin pump delivery can reduce hypoglycemia in individuals with type 1 diabetes

An automated on/off feature built into insulin pump systems can suspend insulin delivery when it detects low blood glucose levels (via continuous glucose monitoring), significantly reducing the severity and duration of hypoglycemia in individuals with type 1 diabetes, according to a study published in Diabetes Technology & Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc.

10 Feb 2012

New cERD method can detect RNAi activity in biological fluids

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that its scientists have discovered a novel method for monitoring RNAi activity in blood samples, representing a potential major advance for future development of RNAi therapeutics, other therapeutic modalities, and diagnostics.

10 Feb 2012

Readministration of gene therapy improves vision in three patients with LCA

Gene therapy for congenital blindness has taken another step forward, as researchers further improved vision in three adult patients previously treated in one eye.

9 Feb 2012

LFA announces new grants for critical areas of lupus research

Today, the Lupus Foundation of America (LFA) announced new research grants awarded to fund critical areas of research where gaps exist in the understanding and knowledge of lupus including: pediatric lupus, cutaneous (skin) lupus, mid-to-late stage translational research, adult stem cells, and neuropsychiatric lupus, which affects the brain and nervous system.

9 Feb 2012

BioMimetic to launch new bone graft substitute product line at AAOS meeting

BioMimetic Therapeutics, Inc. today announced it will introduce Augmatrix Biocomposite Bone Graft, a new bone graft substitute product line, to surgeons and distributors at its exhibit booth during the American Academy of Orthopedic Surgeons (AAOS) meeting this week in San Francisco, CA.

8 Feb 2012

Elan fourth quarter total revenue increases 18% to $271.0 million

Elan Corporation, plc today reported its fourth quarter and full-year 2011 financial results.

8 Feb 2012

TGen to host Pediatric Cancer Translational Genomics in Scottsdale

The Translational Genomics Research Institute (TGen) will host Pediatric Cancer Translational Genomics Feb. 6-8 at the Hotel Valley Ho in Scottsdale, bringing together more than 150 leading pediatric cancer researchers, clinicians and foundations to promote the exchange of information and ideas for advancing pediatric cancer research and treatment.

7 Feb 2012